FOX04-DRI

FOXO4-DRI (FOXO4-D-Retro-Inverso Peptide)

Primary Function: Senescent cell clearance, cellular rejuvenation, anti-aging research
Research Use: Senolytic studies, age-related dysfunction, cancer research, tissue regeneration
Molecular Formula: C130H220N42O37
CAS Number: N/A (custom research peptide)
Synonyms: FOXO4-DRI, FOXO4 peptide inhibitor, Senolytic FOXO4 mimetic

Description:
FOXO4-DRI is a synthetic D-retro-inverso peptide designed to disrupt the interaction between the FOXO4 transcription factor and p53, a key axis that prevents apoptosis in senescent cells. By breaking this bond, FOXO4-DRI allows selective clearance of senescent cells, potentially reducing age-related tissue damage, restoring stem cell niches, and extending healthy cellular function. It has become a cornerstone in senolytic peptide research, often used in advanced anti-aging and regenerative studies.

Mechanism of Action:

• Disrupts FOXO4–p53 binding, triggering apoptosis in senescent cells
• Selectively targets cells with persistent DNA damage and SASP activity
• Preserves healthy, non-senescent cells
• May enhance tissue repair, reduce fibrosis, and improve stem cell viability

Key Research Areas:

• Cellular senescence and longevity studies
• Age-related disease and tissue degeneration
• Cancer therapy support (senescence-resistant tumors)
• Stem cell niche regeneration

History of Discovery:
FOXO4-DRI was developed by Dr. Peter de Keizer and colleagues at the Erasmus University Medical Center (Netherlands) in 2017. Their work demonstrated that this novel peptide could selectively induce apoptosis in senescent cells without harming healthy ones. The discovery marked a breakthrough in senolytic therapeutics, opening new avenues for research in aging, fibrosis, and cancer.

Case Studies:

1. Reversal of Aging in Mice (2017, Cell): Aged mice treated with FOXO4-DRI showed improved kidney function, restored fur density, and increased physical activity. [Cell. 2017;169(1):132–147.e16.]
2. Senescent Cancer Cell Clearance (2019, Aging Cell): FOXO4-DRI sensitized therapy-induced senescent cancer cells to apoptosis, improving response to chemo and radiation. [Aging Cell. 2019;18(3):e12947.]
3. Stem Cell Renewal in Aged Tissues (2020, Oncotarget): Treatment rejuvenated mesenchymal stem cell populations in aged bone marrow models. [Oncotarget. 2020;11(8):712–728.]

Packaging Information:

• Form: Lyophilized powder
• Purity: ≥ 99%
• Storage: Store at -20°C in a dry, dark environment
• For research use only. Not for human or veterinary use.